Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for ...

(Cognito Therapeutics) The Hope study will task upwards of 400 people with mild to moderate Alzheimer’s with using the noninvasive device at home every day for 12 months, throughout which they ...

One startup is testing whether a "disco" of light and sound can slow the disease in patients. Cognito Therapeutics raised $73 million to test this theory in hundreds of people. For decades ...

But startup Cognito Therapeutics is taking a drug-free approach to treating the memory-robbing disease. The Cambridge, Massachusetts–based company is developing a headset to combat cognitive ...

Dr. Rick Kuntz, former Senior Vice President, Chief Medical and Scientific Officer at Medtronic, joins Cognito Board of Directors. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage company developing a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, announced ...

Cognito’s analysis compared participants treated in the Overture study, which enrolled 76 people, to historical data collected from a separate, decade-long, global study conducted by the ...

Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for an elusive target: cognitive decline. Cognito, based in Cambridge, Mass., is developing a headset that ...